Arcoris Bio Raises CHF 6.3 Million to Advance MUSE Nanotechnology Platform for Digital Pathology
Key Insights
Arcoris Bio (search), a Swiss life science company, secured CHF 6.3 million in an oversubscribed seed financing round co-led by Ventura Ace (search) and ZEISS Ventures (search) to commercialize its MUSE biomarker detection platform.
The MUSE platform uses nanotechnology to enable simultaneous detection of multiple biomarkers with high sensitivity and operational simplicity, addressing critical gaps in digital pathology workflows.
The funding will support industrialization of the platform, formation of strategic partnerships, and launch of new products to meet growing demand in precision medicine and drug discovery applications.
Arcoris Bio (search), a Swiss life science research tools and in vitro diagnostics company based in Schlieren, has successfully raised CHF 6.3 million in an oversubscribed seed financing round to advance the commercialization and development of its breakthrough MUSE biomarker detection platform. The funding round was co-led by Ventura Ace (search) and ZEISS Ventures (search), with additional participation from Zürcher Kantonalbank (search) and both new and existing private investors.
Revolutionary Nanotechnology Platform
The company's MUSE platform applies a nanotechnology-driven approach to enable simultaneous detection of multiple biomarkers with unprecedented ease and sensitivity. This capability allows researchers to measure several difficult-to-detect biomarkers within a single sample at higher throughput, positioning the technology to play a pivotal role in the evolution of digital pathology.
"MUSE enables researchers to detect multiple biomarkers simultaneously with unprecedented ease and sensitivity," the company stated, emphasizing the platform's potential to significantly enhance research and clinical capabilities as precision medicine, complex disease classification, and data-driven diagnostic methodologies continue to expand across healthcare and pharmaceutical research sectors.
Strategic Investment and Market Validation
The financing represents a significant milestone for Arcoris Bio (search) as it works to scale operations to meet growing industry demand and accelerate market entry. CEO Matyas Vegh commented on the achievement: "Securing this financing marks a major milestone for arcoris bio. In a challenging market, we are grateful for the trust our investors have placed in our vision. Their support empowers us to bring our innovations to market faster, strengthen our operations, and scale to meet growing industry demand."
Co-founder and CSO Simon Restrepo highlighted the strategic value of the investor partnership: "Attracting two lead investors with deep industry expertise is a strong validation of our technical and business strategy. This support empowers us in our mission of transforming biomarker detection and digital pathology."
Investor Perspective and Technology Impact
Investors expressed strong confidence in the platform's market potential and technical capabilities. Andreas Jenne, Investment Director at Ventura Ace (search), stated: "We have been impressed by the arcoris bio (search) team's vision and early traction with industry partners. We believe MUSE represents a truly enabling technology for digital pathology."
Benedikt Klaes, Senior Investment Manager at ZEISS Ventures (search), emphasized the technology's broad applicability: "arcoris bio (search)'s MUSE technology fills a critical gap in the market to enable better diagnostics and applications like drug discovery or precision medicine. Its universal applicability is particularly exciting – MUSE acts like a molecular GPU, amplifying the capabilities of existing biomarker platforms and opening new paths for innovation."
Commercialization Strategy
The funding will specifically support the industrialization of the MUSE platform, the formation of new strategic partnerships, and the launch of additional product offerings aimed at broadening the technology's impact in digital pathology workflows. The company aims to address unmet needs in digital pathology and biomarker quantification, with applications spanning diagnostics, drug discovery, and precision medicine research.
The ability to measure multiple biomarkers in a single sample at higher throughput is seen as increasingly crucial as the healthcare and pharmaceutical research sectors continue to embrace more sophisticated diagnostic methodologies and personalized treatment approaches.